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Abstract
The surge in reports of heme-dependent proteins as catalysts for abiotic, synthetically valuable 
carbene and nitrene transfer reactions dramatically illustrates the evolvability of the protein world 
and our nascent ability to exploit that for new enzyme chemistry. We highlight the latest additions 
to the hemoprotein-catalyzed reaction repertoire (including carbene Si–H and C–H insertions, 
Doyle-Kirmse reactions, aldehyde olefinations, azide-to-aldehyde conversions, and intermolecular 
nitrene C–H insertion) and show how different hemoprotein scaffolds offer varied reactivity and 
selectivity. Preparative-scale syntheses of pharmaceutically relevant compounds accomplished 
with these new catalysts are beginning to demonstrate their biotechnological relevance. Insights 
into the determinants of enzyme lifetime and product yield are providing generalizable cues for 
engineering heme-dependent proteins to further broaden the scope and utility of these non-natural 
activities.
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Introduction
The rapidly growing implementation of biocatalysis for production of chemicals is driven by 
the ability of enzymes to operate under mild, aqueous reaction conditions with high rates 
and selectivity. The result can be a significant reduction in industrial waste and cost of 
production compared to stoichiometric syntheses and other catalytic processes. The 
importance of directed evolution and other protein engineering tools for tuning enzyme 
activity, selectivity or stability to meet industrial process requirements has been thoroughly 
established [1,2]. However, a significant hurdle is presented by the fact that a number of 
valuable chemical transformations, including many catalyzed by synthetic catalysts, do not 
have biocatalytic counterparts. The necessary enzymes simply do not exist. One effective 
approach to creating new enzymes has been to engineer existing proteins to exhibit new, 
synthetically useful reactivity, mainly by exploiting their metallo- and other cofactors for 
new chemistry and improving those activities by directed evolution [3–5]. The resulting fully 
genetically-encoded catalysts could, at least in principle, be incorporated into in vivo 
biosynthetic pathways to access new products or provide alternative routes to existing 
products. Repurposing existing proteins for new chemistry, a trick used by evolution for 
eons, has proven particularly fruitful with heme-dependent proteins. In this review we cover 
the most recent developments as well as some of the key limitations in this growing area.
In a seminal paper, Coelho and coworkers demonstrated that cytochrome P450BM3 and other 
heme-containing proteins can catalyze the cyclopropanation of styrene using ethyl 
diazoacetate (EDA) as a carbene precursor [6]. Their work was inspired by the well-
established capacity of ‘biomimetic’ metalloporphyrin complexes to catalyze carbene and 
nitrene transfer reactions, providing ample options for the introduction of C–C, C–N and 
other bonds into organic compounds. Coelho et al. further demonstrated that the activity and 
stereoselectivity of cytochrome P450BM3 as a cyclopropanation biocatalyst could be 
improved by mutating the protein. The evolvability of P450BM3 for this abiotic activity was 
underscored in subsequent reports showing that replacement of the conserved P450 axial 
cysteine residue with serine [7] or histidine [8] significantly boosts cyclopropanation 
activity. Furthermore, P450 variants catalyzed carbene N–H insertion to make new C–N 
bonds [9]. The new activities were not limited to carbene transfer reactions: P450 variants 
were shown to catalyze intramolecular nitrene C–H insertion reactions [10,11], and ‘P411s’ 
with an axial Cys-to-Ser mutation were shown to be competent catalysts for sulfimidation 
[12], aziridination [13], and intramolecular C–H amination [14,15] reactions. In each case, 
the observed activities were found to exceed those of previously-reported transition metal 
complexes.
Fasan and coworkers showed that these novel activities are not restricted to cytochrome 
P450s: the small, well-expressed, oxygen-transport hemoprotein myoglobin can become a 
powerful and selective cyclopropanation [16], carbene N–H and S–H insertion [17,18], and 
intramolecular C–H amination catalyst [19]. These contributions, including the underlying 
concepts of chemical intuition and enzyme promiscuity guiding the discovery and 
enhancement of these non-biological activities, have been reviewed in detail [5,20,21].
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In this review, we focus on three recent, concurrent developments. First, we discuss how the 
earlier studies paved the way to the discovery of yet more non-natural carbene and nitrene 
transfer reactions mediated by engineered hemoproteins and how the cornucopia of existing 
hemoproteins is being leveraged to discover new, unprecedented reactivities. Second, we 
show how the field is transitioning from proof-of-concept studies towards implementation, 
with several studies demonstrating preparative-scale production of pharmaceutically relevant 
compounds. Third, we illustrate how the growing body of literature, including recent reports 
of mechanism-based enzyme inactivation, provide stimulus for further protein engineering to 
address what controls (and limits) these non-natural activities of hemoproteins.
New carbene transfer reactions catalyzed by engineered heme proteins
A compelling demonstration of the power of hemoprotein engineering to create a new 
enzyme is the recent report of biocatalytic carbon-silicon bond formation [22••], an activity 
not known in the biological world (Figure 1). Current rhodium, iridium and copper 
complexes developed to promote asymmetric carbene insertions into Si–H bonds of silanes 
all have limited catalytic efficiencies (<100 total turnovers (TTN)). Testing a variety of 
proteins for carbene insertion into the Si-H bond of phenyldimethylsilane, Kan et al. 
discovered that a variety of hemoproteins produce the organosilicon product with 10 to 50 
TTN, although with low enantio-induction [22••]. A highly thermostable cytochrome c from 
the marine bacterium Rhodothermus marinus (Rma), however, catalyzed the transformation 
with excellent enantioselectivity (97% ee). Subsequent directed evolution by mutagenesis of 
active-site residues yielded an Rma cytochrome c triple variant (V75T,M100D,M103E), 
which provided 70% isolated product yield in preparative-scale (0.1 mmol) bacterial whole-
cell reactions with 98% ee and 3,400 TTN. The enzyme exceeded the activity of the best-
reported synthetic catalysts by up to 80-fold, while accepting a range of silane substrates and 
showing a high chemoselectivity for Si–H insertion over cyclopropanation or N–H insertion, 
a feature not exhibited by small-molecule transition metal catalysts.
Mechanistic investigations of myoglobin-catalyzed S–H insertion reactions [18] provided a 
basis for developing catalysts that promote the [2,3]-sigmatropic rearrangement of allylic 
and propargylic sulfides in the presence of α-diazoester reagents [23•]. While this Doyle-
Kirmse reaction provides a powerful C–C bond forming strategy for the synthesis of 
compounds bearing a new stereogenic center, synthetic catalysts exhibit only modest 
catalytic efficiency and low enantioselectivity (<10–50% ee). In contrast, the myoglobin 
triple mutant Mb(L29S,H64V,V68F) showed high product conversions (57–99%), high total 
turnovers (1,000–8,800 TTN), and up to 71% ee across a range of substrates. The scope of 
the reaction could be extended to conversion of propargylic sulfides to give allenes, which 
are valuable synthetic intermediates. A representative [2,3]-sigmatropic rearrangement 
product (ethyl 2-(phenylthio)pent-4-enoate) was isolated in 84% yield.
In another study, Tyagi et al. engineered myoglobins for aldehyde olefination reactions [24], 
providing a convenient and mild alternative to the widely used Wittig reaction. Screening of 
Mb active-site variants identified Mb(F43V,V68F), which converts a broad range of aryl 
aldehydes and alkyl α-diazo acetates into the corresponding olefin products with high 
catalytic efficiency (1,000–4,900 TTN) and very good to excellent trans selectivity (91–99% 
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de). The TTNs reported for the Mb variant are 10- to 100-fold higher than those for similar 
transformations catalyzed by organometallic complexes working in organic solvents and at 
elevated temperature. Mb product conversion was found to not exceed 50%, however, due to 
inhibition by the phosphine (or arsine) oxide side product generated during the reaction.
Focusing on a similar reaction, Hauer and coworkers mined the E. coli proteome in search of 
enzymes capable of catalyzing the olefination of benzaldehyde in the presence of EDA [25]. 
The most promising biocatalyst they identified was YfeX, a heme-containing protein of 
unknown function. Under optimized conditions, this hemoprotein showed 92% selectivity 
for the trans olefin product, albeit at low product conversions (<5%) and with only 15–20 
turnovers. Interestingly, YfeX-catalyzed benzaldehyde olefination was reported to take place 
in the absence of triphenylphosphine/arsine, suggesting that this transformation may involve 
a different mechanism than that proposed for myoglobin-catalyzed aldehyde olefination 
[24].
Progress in terms of substrate scope and synthetic utility is also being made with enzymatic 
cyclopropanation. Gober et al. recently reported cyclopropanation of dihydroalanine (DHA) 
residues contained in thiopeptides, a class of ribosomally synthesized peptides with a range 
of bioactivities, to yield 1-amino-2-cyclopropane carboxylic acid moieties [26]. Two P450 
enzymes involved in monooxygenation reactions within the bacterial thiopeptide biogenesis 
pathway were engineered to harbor mutations previously found to be beneficial for 
promoting P450-mediated cyclopropanation [27•]. The resulting P450 variants were able to 
catalyze the cyclopropanation of DHA moieties in peptide model substrates and in complex 
linear and cyclic thiopeptide cores, offering new opportunities for thiopeptide 
functionalization. In another recent report, Tinoco et al. introduced a two-compartment, 
chemobiocatalytic strategy for realizing olefin cyclopropanation reactions in the presence of 
2-diazo-1,1,1-trifluoroethane (CF3CHN2) as the carbene source. This transformation yields 
trifluoromethyl-substituted cyclopropanes, which are valuable building blocks for medicinal 
chemistry [28•]. In this system, gaseous CF3CHN2 was generated ex situ and subsequently 
utilized by whole-cell catalysts expressing engineered Mb cyclopropanation variants. This 
approach was applied to a range of vinylarene substrates to deliver the corresponding 
trifluoromethyl cyclopropanes in high yields and with excellent diastereo- and 
enantioselectivity.
A detailed account of artificial metalloenzymes containing non-native cofactors is beyond 
the scope of this short review, and this subject has been reviewed recently [4,29]. However, 
we will briefly describe how substitution of the heme cofactor with non- native 
metalloporphyrins is emerging as an alternative strategy for engineering biocatalysts for 
carbene and nitrene transfer reactions. Brustad and coworkers evolved variants of P450BM3 
that are capable of incorporating iron-deuteroporphyrin IX, demonstrating the feasibility of 
engineering cytochrome P450 variants with orthogonal cofactor specificity [30]. Bordeaux et 
al. demonstrated that Mb variants incorporating a non-natural Mn- or Co-porphyrin IX 
cofactor catalyze intramolecular C–H amination reactions with sulfonyl azides, with 
reactivities comparable to their iron-containing counterpart [19]. This work was recently 
expanded by Sreenilayam et al., who reported the recombinant expression of Mb variants 
incorporating various first, second and third row transition metal cofactors (Mn, Co, Ru, Rh, 
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Ir) [31]. The resulting Mb variants were catalytically active in cyclopropanation, N-H and S-
H insertion reactions albeit with generally reduced efficiency compared to the iron-
containing counterparts. Notably, Mn- and Co-substituted Mb variants showed activity for 
an intermolecular carbene C–H insertion reaction with phthalan and EDA, a reaction not 
supported by the iron- containing myoglobins and previously achieved only using an Ir-
containing biocatalyst (vide infra).
By replacing the heme in myoglobin and the thermostable P450 CYP119 with Ir(Me)- 
mesoporphyrin IX, Hartwig and coworkers expanded the reactivity of these hemoproteins to 
carbene C–H insertion [32••,33]. Most notably, Ir(Me)-PIX-substituted variants of CYP119 
catalyzed intramolecular carbene C–H insertion of various ethyl 2- diazo-2-(2-
methoxyphenyl)acetate derivatives with 120–600 TTN and 76–98% ee, and up to 35,000 
TTN under very low catalyst loadings (0.00125 mol%). The CYP119- derived biocatalysts 
were also found to be active for the intermolecular carbene C–H insertion reaction with 
phthalan and EDA. Ir-substituted CYP119 variants were also shown to be active catalysts for 
the cyclopropanation of olefins currently not accepted by Fe-containing enzymes, including 
various internal, aliphatic and electron-deficient alkenes [34]. These artificial enzymes have 
the shortcomings of requiring a cofactor containing rare and expensive metal (Ir) and 
specialized in vitro reconstitution or expression protocols for their assembly. This may limit 
the range of hemoprotein scaffolds that can be used and potentially complicates any effort to 
couple these enzymes to other activities in vivo. Whether these limitations can be overcome 
or whether engineered hemoprotein variants containing the native iron heme cofactor can 
access such challenging reactions as carbene C–H insertion remains to be shown.
Nitrene transfer reactions catalyzed by engineered hemoproteins
Among the new, non-natural activities discovered for hemoproteins are a variety of nitrene 
transfer reactions previously reported using transition metal complexes and, in one early 
case, a cytochrome P450 [35] (Figure 2). Recent studies established that cytochrome P450s 
and other heme-dependent enzymes (horseradish peroxidase, catalase, chloroperoxidase) 
and proteins (myoglobin, hemoglobin) can activate arylsulfonyl azide substrates and 
catalyze their conversion into sultam products via an intramolecular C–H amination reaction 
[11,14,15,19]. Subsequent studies expanded the scope of P450-catalyzed intramolecular C–
H aminations in the context of carbonazidates, enabling the synthesis of protected forms of 
1,2-aminoalcohols, which are valuable synthetic intermediates [10]. Other studies revealed 
that P450 variants from the serine-ligated cytochrome ‘P411’ lineage in combination with 
tosyl azide reagents can catalyze intermolecular nitrene addition to sulfides (sulfimidation) 
and alkenes (aziridination) [12,13].
Additional synthetically useful nitrene-mediated transformations have appeared in the last 
two years. Prier et al. leveraged the high sulfimidation reactivity of P411 enzymes to 
catalyze the conversion of phenylallylsulfides into allylic amines [36•]. This reaction 
involves a spontaneous [2,3]-sigmatropic rearrangement of the sulfimidation product 
generated by the P411-catalyzed reaction between the allyl sulfide and tosyl azide. Carrying 
out these transformations in whole cells, the authors discovered that the intracellular 
environment results in loss of the thiophenol group, effectively leading to the formation of 
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protected allylic amines. Starting from an initial P411 variant catalyzing this reaction with 
only moderate activity (<5% conversion), a significantly more efficient biocatalyst (P-5) was 
obtained after several rounds of directed evolution (79% conversion; 2,000 TTN). 
Importantly, the evolved enzyme also featured high enantioselectivity in both the 
sulfimidation (88–98% ee) and the sulfimidation/sigmatropic rearrangement reactions (68–
82% ee).
Giovani et al. have shown that engineered myoglobins can catalyze the oxidative 
deamination of benzylic azides to yield aldehydes [37•], providing a biocatalytic alternative 
for aldehyde synthesis by alcohol oxidation with chromium- or manganese-based reagents. 
Myoglobin variant Mb(H64V,V68A) converted a broad range of primary azides to the 
corresponding aldehydes with up to 89% yield, exhibiting between 100- and 1000-fold 
higher catalytic activity than previously reported synthetic catalysts. In an extension of this 
study, investigation of a broader panel of hemoproteins revealed that engineered P450s 
catalyze the same reaction with high efficiency and selectivity [38]. A P450BM3 variant 
previously determined to be active in C–H amination reactions enabled the nearly 
quantitative conversion of benzyl azide to benzaldehyde at a catalyst loading of only 0.01 
mol% (>10,000 TTN). This enhanced reactivity enabled the conversion of secondary azides 
to ketones (49–76%), a transformation that proceeds to only <2% conversion in the presence 
of Mb(H64V,V68A).
Interestingly, Carrera and coworkers recently reported the enzymatic transformation of 
benzyl azide to benzonitrile using a Rieske non-heme iron oxygenase (toluene dioxygenase) 
[39]. While not involving a heme enzyme, this reaction was proposed to involve catalytic 
intermediates that are reminiscent of those implicated in hemoprotein-catalyzed nitrene C–H 
insertion [11] and azide oxidation [37•].
Another noteworthy contribution relates to the recent application of engineered P450s for 
the synthesis of imidazolidin-4-ones via an intramolecular oxidative C–H amination [40]. 
While this reaction does not involve a nitrene-mediated process per se, it represents a 
previously undocumented enzymatic transformation useful for the creation of new C–N 
bonds, which further highlights the functional plasticity of cytochrome P450 enzymes.
Finally, Prier et al. recently demonstrated P450-mediated intermolecular amination of 
benzylic C–H bonds [41•]. The authors discovered that a P411 variant evolved for the 
imidation of allylic sulfides [36•] displays activity for the amination of 4-ethylanisole with 
tosyl azide. Subsequent rounds of directed evolution delivered variant P411CHA, providing 
up to 1300 TTN and 99% ee for benzylic C–H amination of a range of alkylarene substrates. 
Engineering the enzyme scaffold endows the native iron heme cofactor, by itself an inactive 
C–H amination catalyst, with activity for a challenging non-natural reaction.
Preparative-scale synthesis of cyclopropane pharmaceutical intermediates
Efforts to utilize these new biocatalysts for the preparation of high-value compounds are 
already starting to appear. In a first example, Wang et al. demonstrated the utility of an 
engineered P450-based carbene transfer catalyst, P450BM3 HStar, for producing the chiral 
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precursor to the antidepressant levomilnacipran in a single biocatalytic step [8]. Applying 
P450BM3 HStar in whole-cell reactions, the cyclopropane core of levomilnacipran was 
obtained in 86% isolated yield, 96% de and 92% ee (Figure 3A). Another recent study used 
myoglobin-based cyclopropanation catalysts for preparative-scale synthesis: applying a 
structure-reactivity guided approach, Bajaj et al. engineered a panel of myoglobin variants to 
access trans-(1R,2R)-configured aryl-substituted cyclopropanes [42•], complementing the 
stereoselectivity of a previously developed trans-(1S,2S)-selective Mb(H64V,V68A) 
cyclopropanation catalyst [16]. Using these biocatalysts in whole-cell transformations 
yielded gram-scale amounts (up to 4.7 g) of the chiral cyclopropane cores of four drugs 
(tranylcypromine, tasimelteon, an investigational TRPV1 inhibitor, and ticagrelor) (Figure 
3B–E). The desired trans-(1S,2S)- or trans-(1R,2R)-configured cyclopropane intermediates 
could be obtained in high yield (75–91%) and significantly higher diastereo- and 
enantioselectivity (98–99.9% de, 96–99.9% ee) than was possible with asymmetric 
cyclopropanation protocols adopted in the process-scale syntheses of these compounds. In 
the case of ticagrelor, the biocatalytic reaction offers a significantly shorter route (2 vs. 4–5 
steps) to preparation of its chiral cyclopropane core compared to previously reported 
methods. In a parallel study, Hernandez and colleagues also reported the stereoselective 
synthesis of the ticagrelor cyclopropane (Figure 3B) using an engineered variant of group II 
truncated hemoglobin from Bacillus subtilis. Mutation of active-site residues in this protein 
led to an improved variant (Y25L,T45A,Q49A), which produced the desired enantiomer in 
79% yield, 96% de and 99% ee in 0.4 mmol-scale reactions [43]. The above studies 
highlight the biotechnological relevance of these new enzymes and underscore the 
advantages of testing a variety of protein scaffolds to find the best starting points for 
achieving desirable transformations and selectivities.
Current limitations
P450 oxygenases, myoglobins, and other hemoproteins have evolved dedicated mechanisms 
to limit self-inactivation through oxidative damage by reactive oxygen species in P450s or 
oxidation to metmyoglobin. However, they have not had a chance to evolve comparable 
protection from the reactive intermediates produced in the active site during carbene and 
nitrene transfer reactions. This issue was recently addressed by Renata et al., who showed 
that a proficient P450 cyclopropanation variant, P450BM3 HStar, undergoes mechanism-
based inactivation whereby the reactive carbene species generated in the active site is 
transferred to nucleophilic groups on the porphyrin ring and enzyme side chains [44•] 
(Figure 4A). These alkylation side reactions severely limit catalyst lifetime. Substitution of 
affected amino acid residues with non-nucleophilic residues resulted in a variant with ~2-
fold improved activity (TTN). Nevertheless, the variant is still alkylated at various sites and 
has a short catalyst lifetime, highlighting significant room for further improvement.
Nitrene transfer catalysts suffer from a different problem. All hemoprotein-catalyzed nitrene 
transfer reactions reported to date are accompanied by unproductive consumption of the 
azide substrate to give a sulfonamide (or carbamate) byproduct [10–14,19,36•,41•]. This 
unproductive pathway has been ascribed to over-reduction and protonation of the putative 
heme-nitrene intermediate (Figure 4B) [11]. Consistent with this, mutation of a highly 
conserved residue (T268) implicated in proton transfer to the hydroxoferryl intermediate as 
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part of the native P450 catalytic cycle was found to improve the activity (TTN) of these 
enzymes as C–H amination catalysts [11,14]. The extent of this side reaction also depends 
on the nature of the substrate [11] and optimization of the enzyme active site for a target 
substrate was shown to improve desired product formation, possibly by facilitating 
productive interception of the nitrene [12]. More recently, heme substitution with an Ir-
porphyrin provided another strategy to obtain P450-based catalysts capable of catalyzing the 
intramolecular C–H amination of arylsulfonyl azides with reduced propensity for azide 
reduction [45]. The TTN supported by these artificial enzymes, however, was comparable to 
those of previously reported hemoprotein-based catalysts, which suggests that other 
inactivating mechanisms may be at play. Another, currently unexplored strategy to overcome 
the problem associated with over-reduction of the iron-nitrene intermediate could be the 
engineering of P450 variants with altered (i.e., slower) rates of electron transfer [11].
Outlook - future opportunities for hemoprotein engineering
The preceding sections highlighted how diverse hemoprotein scaffolds can be adapted for 
various carbene and nitrene transfer reactions, with different scaffolds frequently showing 
altered reactivity or selectivity for a given transformation. Future efforts are anticipated to 
continue to take advantage of the wealth of natural hemoprotein scaffolds contained in 
genomic and structural databases (with >3900 hemoprotein structures currently deposited in 
the PDB) [46,47] to unveil catalysts with novel or superior activity or selectivity for 
abiological transformations. The ever-decreasing costs of DNA synthesis render it 
increasingly economical to obtain synthetic (hemoprotein) genes for rapid testing and 
engineering [48]. The nascent activities discovered in this vast collection can then be 
improved and tuned by directed evolution.
The studies reviewed here have begun to provide important clues and guidance for fine-
tuning carbene and nitrene transfer reactivity in hemoproteins by protein engineering. Even 
non-enzyme hemoproteins like myoglobin or cytochrome c can be turned into proficient 
enzymes by “carving out” active sites through mutation of a few selected residues 
surrounding the heme pocket [16,22••,43]. In the context of P450s, Gober and Brustad 
showed that the T268A mutation, previously found to be beneficial for boosting 
cyclopropanation activity in P450BM3 [6], can be transferred to other cytochrome P450s to 
improve cyclopropanation activity [27•]. McIntosh et al. showed that the thermostable P450 
CYP119 can accommodate substitution of its axial Cys residue with His, a mutation that 
also enhances cyclopropanation activity in P450BM3, by undergoing substantial structural 
rearrangement [49]. Intriguingly, soluble CYP119 enzymes with diverse spectroscopic 
characteristics were obtained for all 19 possible axial Cys substitutions, providing a small 
library of diverse potential starting points for further engineering.
Further guidance in hemoprotein engineering may come from computational approaches. 
Using model systems, recent DFT studies have investigated the nature of the putative iron 
carbenoid intermediate, shedding light on factors governing its formation and reactivity [50–
52]. In particular, work by Sharon et al. on carbene N–H insertion [52] indicated that 
altering the basicity of the enzyme active site may allow access to aliphatic amines, 
Brandenberg et al. Page 8
Curr Opin Biotechnol. Author manuscript; available in PMC 2018 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
potentially extending the substrate scope from the aromatic amines reported to date [9,17]. 
This proposal has not yet been tested experimentally.
To date, none of these new catalysts have been utilized in enzymatic cascades or metabolic 
engineering to create new biosynthetic pathways. With most carbene and nitrene transfer 
enzymes showing similar or higher turnovers in whole-cell contexts compared to purified 
enzyme, integrating them into metabolic pathways to produce non-natural chemicals is 
certainly tempting. However, successful realization may require further efforts to engineer 
the enzymes to exhibit lifetimes and kinetic properties (e.g., Km) that are more compatible 
with synthesis in living cells. A proof-of-concept for interfacing microbial metabolism with 
a non-natural reaction was recently published by Wallace and coworkers, who demonstrated 
styrene production from glucose in E. coli with subsequent cyclopropanation using a 
synthetic cyclopropanation catalyst [53•].
In conclusion, the field has come a long way since the initial report of hemoprotein-
catalyzed olefin cyclopropanation just four years ago. The studies reviewed here provide 
ample inspiration for future protein engineering to discover yet more novel reactivities and 
to enhance the catalytic efficiencies of the current, nascent enzymes. Growing genomic 
databases and decreasing costs of DNA synthesis render it increasingly simple to sample 
natural hemoproteins for desired reactivities. Thus, propelled by the lack of biocatalytic 
alternatives for many synthetically useful reactions, we anticipate many more members to 
join the family of hemoproteins catalyzing non-natural reactions.
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Highlights
• Engineered hemoproteins expand the biocatalytic repertoire
• Different hemoprotein scaffolds offer diverse activities and selectivities
• New enzymes enable preparative-scale syntheses of pharmaceutical 
intermediates
• Insights into factors limiting enzyme lifetime offer new options for 
engineering
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Figure 1. Carbene transfer reactions catalyzed by engineered hemoproteins
Carbene transfer by hemoproteins requires reduction of the heme iron from the Fe(III) to the 
catalytically active Fe(II) state. Subsequent encounter with a diazo compound results in 
release of N2 (not shown) and formation of a putative iron carbenoid reactive intermediate. 
Iron carbenoid formation in the heme pocket has been exploited for a range of carbene 
transfer reactions. The iron heme is returned to the catalytically active Fe(II) state (not 
shown) following carbene transfer. While most reactions were achieved with the native iron 
heme cofactor, C–H insertion activity (shown in lighter gray) required replacement of the 
iron heme with an Ir, Mn or Co porphyrin cofactor.
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Figure 2. Nitrene transfer reactions catalyzed by engineered hemoproteins
Enzymatic nitrene transfer requires reduction of the iron heme from the Fe(III) to the 
catalytically active Fe(II) state. Encounter with azide substrates results in release of N2 (not 
shown) and formation of a putative iron nitrenoid reactive intermediate. Iron nitrenoid 
formation by hemoproteins has been exploited in a range of biocatalytic nitrene transfer 
reactions. The iron heme is returned to the catalytically active Fe(II) state (not shown) 
following nitrene transfer.
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Figure 3. Preparative-scale synthesis of cyclopropane-containing drug precursors
Preparative-scale cyclopropanation reactions reported to date using engineered 
hemoproteins, providing access to various pharmaceutical intermediates with excellent 
yields, diastereo- and enantioselectivities.
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Figure 4. Limitations to carbene and nitrene transfer efficiency
(A) Carbene transfer biocatalysts suffer from alkylation of the porphyrin ring or nucleophilic 
protein residues by the reactive carbenoid intermediate, ultimately resulting in enzyme 
inactivation. Replacing nucleophilic residues, as shown by Renata et al. [44•] or otherwise 
promoting productive transfer to the desired substrate could ameliorate the problem and 
deliver improved cyclopropanation enzymes. (B) Nitrene transfer catalysts are affected by 
overreduction/protonation of the heme nitrene intermediate, resulting in unproductive 
consumption of azide substrate. For intramolecular C–H amination, mutation of a residue 
involved in proton transfer within the native P450 catalytic cycle (T268) results in higher 
product formation [11].
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